NCT04364230View on ClinicalTrials.gov

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
MelanomaOcular MelanomaUveal Melanoma
Interventions
DRUG

6MHP

6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

DRUG

NeoAg-mBRAF

BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).

DRUG

PolyICLC

polyICLC, local adjuvant

DRUG

CDX-1140

CDX-1140, local adjuvant

Trial Locations (2)

22908

University of Virginia, Charlottesville

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

Sponsors

Collaborators (1)

Celldex Therapeutics
All Listed Sponsors
collaborator

Celldex Therapeutics

INDUSTRY

lead

Craig L Slingluff, Jr

OTHER

NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | Biotech Hunter | Biotech Hunter